The relation between thyroid hormone changes and cytokines in bone marrow transplantation (BMT) patients has not been studied. This prospective study was designed to determine the relation between thyroid hormones and cytokine levels after BMT and their effects on the mortality. We studied 80 patients undergoing allogeneic BMT. Serum thyroid hormone parameters and cytokine levels were measured before and serially during 6 months after BMT. Serum T 3 decreased to a nadir 3 weeks post-BMT and serum T 4 was lowest at 3 months post-BMT. Serum thyroid stimulating hormone (TSH) sharply decreased to a nadir at 1 week and recovered. Serum interleukin-6 increased for 2 weeks after BMT and declined thereafter. Serum tumor necrosis factor-a increased for 3 weeks after BMT and declined thereafter. After 3 weeks post-BMT, both cytokine levels were negatively correlated with serum T 3 and T 4 levels. A total of 29 patients died before 1 year post-BMT and 51 patients survived longer than 1 year. Those patients who died before 1 year post-BMT had significantly lower levels of T 4 at 3 weeks, 3 and 6 months than surviving patients. In conclusion, increased levels of serum IL-6 and TNF-a were negatively correlated with thyroid hormone concentrations in BMT recipients suggesting the role of these cytokines in euthyroid sick syndrome.
The euthyroid sick syndrome (ESS) concerns changes in the thyroid hormone metabolism in patients with nonthyroidal illness. In cases of mild illness, this involves only a decrease in serum T 3 levels. However, in more seriously ill patients, a drop in both serum T 3 and T 4 occurs. This decrease in serum thyroid hormone levels is observed in starvation, 1 surgery, 2 sepsis, 3,4 myocardial infarction 5 and probably during any severe illness. 6 A marked decrease in serum T 4 is associated with a high probability of death. When serum T 4 levels falls below 4 mg/dl, the probability of death is about 50%, and at below 2 mg/dl the probability of death reaches 80%. [7] [8] [9] [10] In patients undergoing bone marrow transplantation (BMT), the development of ESS indicates a poor prognosis. 11, 12 Recently, attention has been focused on the role of cytokines in the pathogenesis of ESS. An increase in serum interleukin-6 (IL-6) and of tumor necrosis factor-a (TNF-a) concentrations was reported in ESS patients, especially those with low T 3 concentration. [13] [14] [15] [16] Moreover, serum IL-6 levels were negatively correlated with serum FT 3 in ESS. [17] [18] [19] [20] [21] [22] [23] It is generally agreed that ESS is associated with increased cytokine production, but the degree of cytokine involvement and their specific roles in the pathogenesis of ESS remain to be elucidated.
An increasing number of allogeneic BMTs have been carried out worldwide over the past 20 years. BMT provides an opportunity to study the effects of serious illness on thyroid function in a prospective manner, because patients become acutely ill following myeloablative therapy, immune suppression and possibly graft-versus-host disease (GVHD). Several studies have been undertaken regarding changed thyroid function after BMT, but the relation between thyroid hormone changes and cytokines in patients undergoing BMT has not been previously studied. In addition, serial changes of thyroid hormone levels have not been evaluated, especially in the immediate post-BMT period, during which ESS more frequently develops.
Since our hospital is a reference center for BMT, we decided to conduct a cooperative and prospective study between the Departments of Hematology and Endocrinology. The purpose of this study was to characterize the serial changes of serum thyroid hormone parameters and serum cytokine levels and their relationship before and during the early period after allogeneic BMT. We also observed the effect of total body irradiation (TBI) and high-dose steroid therapy on thyroid function changes during the 6 months following allogeneic BMT. The relation of thyroid dysfunction and mortality was also evaluated.
Patients and methods

Patients
We prospectively enrolled 80 (30 female and 50 male) patients undergoing allogeneic BMT for hematologic diseases from October 1998 to August 1999. Exclusion criteria were thyroid disease and the use of thyroid hormones or thyrostatic medication before BMT. Patients who died sooner than 1 month after BMT were also excluded. Underlying diseases of 80 patients were 27 chronic myelogenous leukemia, 23 acute myelogenous leukemia, 13 acute lymphoblastic leukemia, eight severe aplastic anemia, seven myelodysplastic syndrome, one multiple myeloma and one paroxysmal nocturnal hemoglobinuria). The mean age of the patients was 32.777.8 years (mean7s.d., range 19-54) at the time of BMT. Five patients received bone marrow from human leukocyte antigen (HLA)-matched unrelated donors and 75 patients received from HLA-matched related donors. The median follow-up was 25 months (range 2-50 months). Following BMT, 29 patients (36.2%) died before 1 year post-BMT and 51 patients (63.8%) survived longer than 1 year. Thyroid hormone parameters and cytokine levels between those patients who have subsequently died and those surviving were compared. The relation of thyroid hormone parameters and 1-year mortality was analyzed, since we hypothesized that early thyroid dysfunction could predict short-term mortality such as 1 year post-BMT rather than long-term mortality. We also compared thyroid hormone parameters and cytokine levels according to the occurrence of GVHD and type of BMT (related vs unrelated).
A total of 53 patients received TBI (10-13.2 Gy) as a conditioning regimen. Intravenous cyclosporine A, 5 mg/ kg/day 1 day before BMT and 3 mg/kg/day for 20 days after BMT, was administered to all patients in order to prevent GVHD. Thereafter, oral cyclosporine A at 6 mg/ kg/day was begun and continued for 6-12 months. Established GVHD was treated with a combination of intravenous methylprednisolone or oral prednisolone and cyclosporine A. Doses were tapered when clinical control of GVHD was achieved. Most patients received steroid as a pre-medication when platelet transfusions were performed to prevent bleeding due to thrombocytopenia. Some patients received high-dose steroid therapy and oral prednisolone, and this group of patients was classified as the high-dose steroid group (40 patients). The causes for the administration of high-dose steroid in these patients were GVHD, bronchiolytis obliterans organizing pneumonia (BOOP) and Pneumocystis carinii pneumonia. The mean doses of prednisolone administered during the post-BMT first month were 35.474.8 and 11.272.4 mg/day in the high-dose steroid group (n ¼ 40) and the non-high-dose steroid group (n ¼ 40), respectively. The high-dose steroid group arbitrarily contained those patients receiving a prednisolone dose of above a mean 15 mg/day during the first month post-BMT. In all patients, blood was sampled to determine T 3 , T 4 , FT 4 and TSH serum levels before BMT, at 1, 2, 3 and 4 weeks and at 3 and 6 months after BMT.
Serum cytokines (IL-6 and TNF-a) were measured before BMT, and at 1, 2, 3 and 4 weeks and at 3 months after BMT. Correlations between serum thyroid hormone levels and cytokines were evaluated at each time point before, and serially after BMT. Thyroid hormone parameters in patients with TBI or the high-dose steroid group were compared to those of patients without TBI or highdose steroid therapy. We also analyzed the incidence of ESS. Low T 3 syndrome was defined as a serum T 3 level below the normal range at any time point without high TSH level and low T 3 , T 4 syndrome was defined when both serum T 3 and T 4 were below the normal range at any time point without high TSH level during the 6 months post-BMT.
The protocol was approved by the Institutional Review Board of St Mary's Hospital, and informed consent was obtained from all participants.
Methods
All assays were performed on serum samples. Serum T 3 (RIA-mat T 3 , Byk-Sangtec Diagnostica, Germany, normal values: 1.1-2.9 nmol/l) and serum T 4 (RIA-mat T 4 , BykSangtec Diagnostica, Germany, normal values: 64-154 nmol/l) were determined in duplicate by radioimmunoassay. The intra-and inter-assay coefficients of variation (CV) for the range of concentrations evaluated were 3.0 and 5.0% for T 3 and 2.8 and 5.1% for T 4 , respectively. Serum TSH (IRMA-mat TSH, Byk-Sangtec Diagnostica, Germany, normal values: 0.3-3.0 mU/l) was determined by immunoradiometric assay. The intra-and inter-assay CV of TSH were 2.5 and 5.7%, respectively. Serum FT 4 (RIA-mat FT 4 , Byk-Sangtec Diagnostica, Germany, normal values: 9-24 pmol/l) was determined in duplicate by radioimmunoassay. The intra-and inter-assay CV of FT 4 were 2.4 and 7.8%. Serum IL-6 and TNF-a (ELISA kit, Hyundai Pharm. Research Institute, Korea) were measured in duplicate by enzyme-linked immunosorbent assays with detection limits of 4 and 7 pg/ml (reference range: o10 pg/ml), respectively. The maximum intra-and inter-assay CV for the range of concentrations evaluated were 6.2 and 8.3% for IL-6, and 7.0 and 8.2% for TNF-a, respectively. Blood samples were taken between 0700 and 0900 following an overnight fast. After centrifugation (1500 g) for 10 min, aliquots of serum were stored at À201C until analysis.
Statistical analysis
All values are given as means7s.e.m. Wilcoxon's signed rank test was used to analyze the thyroid hormone parameters and cytokine profiles in matched pairs during the pre-and post transplant period. The Mann-Whitney U test or the Moses test was used to compare the thyroid hormone levels according to the presence of TBI or highdose steroid treatment. Correlations between thyroid hormone and cytokine levels were assessed using the Spearman rank test. A P-value of o0.05 was considered to be statistically significant.
Results
Serial changes of thyroid hormones levels after BMT
The mean levels of serum T 3 , T 4 and TSH before BMT were 1.3770.07, 79.473.3 nmol/l and 0.8170.07 mU/l, respectively ( Figure 1 ). For all patients analyzed, mean levels of serum TSH sharply decreased to a nadir at 1 week (Po0.01 against basal value) after BMT and gradually recovered to the basal value at 6 months. Mean levels of serum T 3 decreased significantly at 1 week and declined further to reach a minimum at 3 weeks (Po0.01 vs the basal value). It then began to increase at 4 weeks and gradually reached its pre-BMT basal value at 6 months. Mean levels of serum T 4 increased within the normal range during the 2 weeks following BMT, but then decreased significantly to reach a minimum at 3 months (Po0.05 against basal value), and subsequently recovered to baseline at 6 months. Serum FT 4 significantly increased within normal range for the 3 weeks following BMT (Po0.01) and then gradually returned to its basal level over 6 months ( Figure 1 ). Low T 3 syndrome was found in 47 of 80 patients (58.8%) and low T 3 , T 4 syndrome in other 26 patients (32.5%).
Serial changes of serum cytokines (IL-6, TNF-a) after BMT
Mean levels of serum IL-6 increased over the 2 weeks following BMT (Po0.05 vs baseline) and then declined. Mean levels of serum TNF-a increased for 3 weeks after BMT (Po0.001 vs baseline) and then declined (Figure 2 ).
Serial correlations between serum thyroid hormones and cytokines after BMT
No significant correlation was found between serum thyroid hormone parameters (T 3 , T 4 and TSH) and cytokines (IL-6 and TNF-a) before BMT, or at 1, 2 and 3 weeks after BMT, respectively. However, serum T 3 was significantly correlated with serum IL-6 (r ¼ À0.52; Po0.05) and TNF-a (r ¼ À0.60; Po0.01) at 3 months post-BMT. Serum T 4 also correlated with serum IL-6 at 4 weeks and 3 months (r ¼ À0.56 and À0.50, respectively; both Po0.05) and with serum TNF-a at 3 months (r ¼ À0.56; Po0.05). In subgroup analysis according to TBI and high-dose steroid treatment, above significant correlations were changed to insignificant both in TBI group and high-dose steroid group. However, these correlations remained significant both in non-TBI group and low-dose steroid group.
Differences in thyroid hormone parameters and cytokines in patients with and without TBI or high-dose steroid therapy No significant differences were found in serum T 3 , T 4 and TSH levels between patients with and without TBI, with the exception of serum T 4 levels at 3 weeks post-BMT. Serum TSH levels in patients with TBI tended to be lower than in those without TBI during the entire observation period, but this was without statistical significance. Patients in both groups had similar serum FT 4 levels during the entire period. Patients with TBI had lower level of IL-6 at 4 weeks (73.278.2 vs 283.5735.4 pg/ml, Po0.05). However, no significant differences were found in IL-6 and TNF-a levels between patients with TBI and without TBI, except above parameter.
Patients receiving high-dose steroid therapy had lower T 3 levels on week 3 (Po0.05) and TSH levels on weeks 2 and 3 (Po0.05) than those with low-dose steroid, and this was statistically significant. Serum T 3 , T 4 and TSH levels in patients receiving a high dose of steroid tended to be lower than those of patients taking low steroid doses during the entire period, but this was not significant. Patients in these two groups did not display any differences in serum FT 4 levels during the entire period. No significant differences were found in IL-6 and TNF-a levels between patients with high-dose steroid and those with low-dose steroid during the entire period. Differences in thyroid hormone parameters and cytokines between those patients who have subsequently died before 1 year post-BMT and those surviving
In total, 38 patients died during the follow-up, and 29 patients (37.5%) died before 1 year post-BMT. The time of death was as follows: o3 months (n ¼ 7), 3-6 months (n ¼ 11), 6 months to 1 year (n ¼ 11). The causes of death were relapse, pneumonia, GVHD, CMV infection, pulmonary hemorrhage, BOOP and renal failure. Those patients who have subsequently died before 1 year post-BMT represented lower levels of T 4 However, no significant differences were found in serum T 3 , FT 4 and TSH levels between the two groups.
Patients were divided by serum T 4 level of 4 mg/dl (51.2 nmol/l) at post-BMT 3 weeks because the serum T 4 level of 4 mg/dl was known useful to predict mortality. 10 Patients with serum T 4 below this level at post-BMT 3 weeks were eight out of total 80 patients (10%). Six patients (75%) out of these eight patients with low-T 4 level at 3 weeks died before 1 year post-BMT. When compared to patients with serum T 4 level above 4 mg/dl at 3 weeks, those with serum T 4 level below 4 mg/dl had significantly higher 1-year mortality (odds ratio 6.39, 95% CI: 1.04-50.09). When patients were divided by serum T 3 level at post-BMT 3 weeks, those with low T 3 syndrome had a tendency of higher mortality, but without statistical significance.
No significant differences were found in serum cytokine levels between those patients who have subsequently died before 1 year post-BMT and those surviving. We also could not find the predictive role of serum cytokines on the mortality (data not shown).
Differences in thyroid hormone parameters and cytokines in patients with and without GVHD or related BMT Totally, 54 patients had GVHD. Acute GVHD occurred in 36 patients, chronic GVHD in 13 patients and both in five patients. The grade of GVHD were as follows: I (n ¼ 9), II (n ¼ 20), III (n ¼ 17), IV (n ¼ 8). Patients with GVHD had lower level of IL-6 at 3 months (54.2712.2 vs 181.6746.1 pg/ml, Po0.05), TNF-a at 3 months (66.5710.8 vs 168.4729.1 pg/ml, Po0.05), TSH at 3 weeks (0.1970.04 vs 0.5470.15 mU/l, Po0.05), respectively. However, except above parameters, no significant differences were found in serum thyroid hormone and cytokine levels between patients with GVHD and without GVHD. We also could not find significant differences in thyroid function and cytokine levels according to the severity of GVHD (eg grade I vs grade II-IV, grade I-II vs grade III-IV).
No significant differences were found in serum thyroid hormone and cytokine levels between patients undergoing related BMT (n ¼ 75) and unrelated BMT (n ¼ 5).
Discussion
In this study, we observed the serial changes of thyroid hormone and circulating cytokines after allogeneic BMT, and found that thyroid hormone levels are related to the levels of circulating cytokines. The study also shows that over 90% of BMT recipients display ESS in the early posttransplant period. In a study of 27 patients undergoing BMT, serum T 3 and TSH levels declined rapidly during the first months after BMT. 24 Serum T 4 levels decreased but to a smaller extent and more slowly than serum T 3 levels. 24 The results of the present study are in agreement with previous reports. 24, 25 Serum FT 4 levels significantly increased within normal range for the 3 weeks following BMT. Although these changes in FT 4 levels were statistically significant, the absolute differences appeared to be small and may not have clinical significance because FT 4 levels gradually returned to its basal level over 6 months. In the present study, serum TSH decreased significantly during the period immediately following BMT and then gradually recovered over 6 months. The initial decrease in TSH might be related to steroid administration and TBIrelated hypothalamic dysfunction. It is noteworthy that acute changes in thyroid hormone concentrations in these BMT recipients gradually recovered to pre-BMT levels at 6 months. It suggests that changes in thyroid hormone parameters are not due to intrinsic alterations in thyroid function, but represent only secondary change in response to BMT.
The incidence of ESS after BMT is reported to be 43% at 3 months post-BMT, 11 but no study has assessed the serial changes of thyroid hormone parameters in the earlier post-BMT period, during which ESS development is expected to be more prominent and rapid. In our study, 91.3% patients had ESS, and low T 3 syndrome occurred in 58.8% patients and low T 3 , T 4 syndrome in 32.5% patients over the 6 months after BMT. Our results display that ESS develops frequently in the early post-BMT period, especially during the first month after BMT.
The development of ESS is known to represent poor prognosis after BMT. In a study of 78 patients undergoing allogeneic BMT, the 30-month projected survival time was 83% for patients without thyroid abnormalities but only 49% for patients with abnormal thyroid profiles. 11 In this study, we analyzed the relation of thyroid dysfunction and mortality. Significant differences were found in serum T 4 level between those patients who have subsequently died before 1 year post-BMT and those surviving. The patients with low T 4 level at post-BMT 3 weeks had lower 1-year survival rate than those with normal T 4 level, which is in agreement with previous data. [7] [8] [9] [10] No significant differences in thyroid hormone parameters were found according to the presence or severity of GVHD, which is similar to the finding of Vexiau et al. 11 Cytokines were not significantly different between those patients who have subsequently died before 1 year post-BMT and those surviving.
Increased concentrations of IL-6, and to a lesser extent TNF-a, are often found in ESS patients and correlate with changes in thyroid hormone levels. 26 Increased circulating cytokine levels are associated with several complications of BMT, such as GVHD or infectious episodes. [27] [28] [29] However, no study has been undertaken on the relation between thyroid hormone changes and cytokines in patients undergoing BMT. The present study shows that serum IL-6 and TNF-a increases significantly after allogeneic BMT, and that the concentrations of both cytokines are inversely related with serum T 3 or T 4 at 3 months post-BMT. Other evidences are currently available that favor the role of cytokines in the pathogenesis of ESS. In cultured human thyrocytes, IL-6 and TNF-a inhibited TSH-stimulated T 3 secretion, 30, 31 and the administration of IL-6 or TNF-a in humans was followed by a significant decrease in serum T 3 and TSH concentrations, and an increase in serum rT 3 levels. 32, 33 Neutralization of the effects of IL-6 by anti-IL-6 antibody was reported in animals. 34 In a recent study, Nagaya et al 35 found that NF-kB activation by TNF-a is involved in the pathogenesis of ESS and that the inhibition of NF-kB activation could help prevent a decrease in serum T 3 levels, and thus ameliorate ESS. Contrary to this evidence, other experimental and clinical data indicate that cytokines are not involved in ESS. Although increased serum IL-6 levels were found in children with acute respiratory infections and in brain-dead patients, TNF-a and IL-1 concentrations were generally normal. 18, 19 Boelen et al 36 studied the levels of interferon-g, IL-8 and IL-10 in ESS patients and found no evidence that they had a pathogenic role.
We performed multiple statistical comparisons between two groups according to TBI or high-dose steroid administration, thus by chance alone, it is possible that one or two of those tests could be statistically significant without any clinical significance. We should be careful in determining its real significance.
In the present study, it was observed that serum TSH levels were not correlated with circulating cytokines during the entire study period, which is in contrast to results of van der Poll et al. 32 This disagreement may be due to the many differences between the studies, which include steroid administration, immunosuppressants and the effect of TBI and cytokines in our study. It is known that serum TSH levels decrease following TBI or high-dose steroid therapy via the suppression of the hypothalamic-hypophyseal function. [37] [38] [39] In our study, patients with TBI or highdose steroid showed a tendency to have lower TSH levels than those without TBI or high-dose steroid. Serum T 3 and T 4 also tended to be lower in the patients with high-dose steroid than in the other patients. It is thought that highdose steroid may influence overall changes in thyroid function after allogeneic BMT.
Our study implies that ESS develops frequently following allogeneic BMT, and that the associated changes take until 6 months post-BMT to recover. Increased levels of cytokines including IL-6 and TNF-a were found in post-BMT patients and were inversely correlated with the levels of thyroid hormones. Further observation is needed to determine the prognostic value of post-BMT ESS in BMT recipients.
